BUSINESS UPDATE

2 years ago

Arecor Therapeutics plc(“Arecor” or the “Group”) BUSINESS UPDATE Pipeline for future revenue generating partnered collaborations is strong with further deals…

Clene Reports Significantly Decreased Mortality in RESCUE-ALS Long-Term Open Label Extension Trial

2 years ago

As of the July 5, 2022, data cutoff, early CNM-Au8® treatment resulted in a significant survival benefit (5 CNM-Au8 deaths…

Tilray Brands to Announce Fourth Quarter and Fiscal Year 2022 Financial Results on July 28, 2022

2 years ago

LEAMINGTON, Ontario, July 14, 2022 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray Brands” or the “Company”) (Nasdaq | TSX: TLRY),…

BioAdaptives, Inc. Launching Next Generation Products for Natural Health Practitioners

2 years ago

Enhanced products For Use by Holistic Healthcare Practitioners – $21b US Market For Alternative Medicine Goods and Services LAS VEGAS,…

Theratechnologies Provides Update on the Dose Escalation Portion of Fast Track Designated TH1902 First-in-Human Study in Advanced Resistant Malignancies

2 years ago

Confirmed safety profile at 300 mg/m2 or 1.5 times the therapeutic dose of docetaxel aloneConfirmed low levels of free docetaxel…

Teleflex Announces Second Quarter 2022 Earnings Conference Call Information

2 years ago

WAYNE, Pa., July 14, 2022 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its second…

InvestmentPitch Media Video Discusses Reliq Health, a Rapidly Growing Global Telemedicine Company, Continues its Growth, Adding 3 New US Contracts and a Significant New Sales Partnership

2 years ago

VANCOUVER, British Columbia, July 14, 2022 (GLOBE NEWSWIRE) -- Reliq Health Technologies Inc. (TSXV:RHT) (OTCPink:RQHTF) (FSE:MHN2), a rapidly growing global…

Mendus AB: Mendus Publishes Preclinical Data Demonstrating Significant Anti-Tumor Synergies of Intratumoral Immune Priming with CTLA-4 Inhibition

2 years ago

Intratumoral injection of allogeneic pro-inflammatory dendritic cells (“ilixadencel”) substantially and sustainably enhanced an otherwise ineffective systemic anti CTLA-4 treatment in…

Press Release: Dupixent® (dupilumab) Phase 3 trial shows positive results in children 1 to 11 years of age with eosinophilic esophagitis

2 years ago

 Dupixent®(dupilumab) Phase 3 trial shows positive results in children 1 to 11 years of age with eosinophilic esophagitis First and…

Healthcare Triangle Announces Closing of $6.5 Million Private Placement

2 years ago

PLEASANTON, Calif., July 13, 2022 (GLOBE NEWSWIRE) -- Healthcare Triangle Inc., (Nasdaq: HCTI) (“HCTI” or the “Company”), a leading provider…